ABOUT
REVESTIVE is indicated for the treatment of adult and paediatric patients 2 years of age and above with Short Bowel Syndrome (SBS) who are dependent on parenteral support.1
Patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy.1
Patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy.1
About REVESTIVE – Adult
A booklet for healthcare professionals to learn more about REVESTIVE, and its impact on the lives of adult patients.
About REVESTIVE – Paediatric
A booklet designed to help healthcare providers understand REVESTIVE’s impact on paediatric patients with SBS-IF.
Understanding the clinical data
PBS Information: This product is listed on the PBS. Authority required. Refer to PBS Schedule for full authority information.
Click here to review full approved Product Information before prescribing.
| ▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems |
REFERENCES
- REVESTIVE Product Information